PremiumRatingsAkero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target Akero Therapeutics price target lowered to $78 from $80 at Citi Akero Therapeutics Advances in MASH Treatment Research PremiumRatingsPromising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating Akero Therapeutics announces new analyses of Phase 2b HARMONY trial PremiumThe FlyAkero Therapeutics initiated with a Buy at Clear Street Akero Therapeutics: Strong Financials and Promising Clinical Progress Justify Buy Rating Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics 
